Apalutamide Impurity 13(CAS: 2227589-22-0)

Apalutamide Impurity 13 (CAS: 2227589-22-0) must comply with global regulatory guidelines such as REACH in the EU, TSCA in the US, and GHS for hazardous classification. It is important to adhere to specific handling, storage, and disposal requirements as outlined by the respective authorities to ensure safety and compliance.

Alternatives to Apalutamide Impurity 13 (CAS: 2227589-22-0) include using isomers or analogs that can serve similar functional roles in synthesis. Common reagents and catalysts can also be adjusted to achieve the desired product without producing this specific impurity.

The market for Apalutamide Impurity 13 (CAS: 2227589-22-0) is closely tied to the broader market for apalutamide, a drug used in the treatment of prostate cancer. Research trends focus on optimizing synthesis methods to minimize this impurity and improving drug efficacy and safety.

Waste containing Apalutamide Impurity 13 (CAS: 2227589-22-0) should be collected in leak-proof containers, labeled appropriately, and disposed of through professional waste disposal services. Incineration or other regulated disposal methods may be required to ensure environmental safety and compliance with local regulations.